From: Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients
Total (n = 32) | CGC1(ALL) (n = 12) | CyGC2(NHL) (n = 20) | P^ 1 vs. 2 | |
---|---|---|---|---|
Age (yrs.)* | 38.4 ± 18.7 | 34.3 ± 21.5 | 40.8 ± 16.7 | 0.35 |
Gender, n (%) | ||||
Male | 15 (46.8) | 6 (50) | 9 (45) | 0.82 |
Female | 17 (53.2) | 6 (50) | 11 (55) | 0.76 |
BMI † | ||||
<20 | 2 (6.3) | 1 (8.3) | 1 (5) | 0.88 |
20-24.9 | 7 (21.9) | 2 (16.7) | 5 (25) | 0.45 |
25 – 29.9 | 14 (43.7) | 4 (33.3) | 10 (50) | 0.23 |
≥30 | 9 (28.1) | 5 (41.7) | 4 (20) | 0.19 |
W/H ratio, n (%) | ||||
≥0.8 | 29 (90.6) | 9 (75) | 20 (100) | 0.81 |
<0.8 | 3 (9.4) | 3 (25) | 0 | 0.12 |
PAD mg/patient | ||||
8 weeks | - | 4,200 | 1,500 | - |
12 weeks | - | - | 2,500 | - |
AN, n (%) | 4 (12.5) | 2 (16.7) | 2 (10) | 0.70 |
Family history DM, n (%) | 20 (62.5) | 10 (83.3) | 10 (50) | 0.11 |